|
| Register for our Free Newsletters |
|
 |
|
|
|
|
|
|
|
|
| Other Carouselweb publications |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Debiopharm partners Ecole Polytechnique Federale de Lausanne in stem cell project
|
|
Debiopharm
: 03 September, 2008 (Company News) |
|
|
Debiopharm Group has signed a research project agreement with the Ecole Polytechnique Federale de Lausanne (EPFL), which is aimed at the identifying novel small molecules and peptides that interfere with pathways controlling cell fate specification. |
|
The project, named Debio 0826, could lead to the development of potential therapeutic compounds and to the identification of new targets to fight cancer stem cells.
Following the signature of an EPFL-Debiopharm partnership on February 12, 2008 this first joint research project will be performed under the supervision of Dr Freddy Radtke, associate professor at the Swiss Institute for Experimental Cancer Research (ISREC) and Dr Gerardo Turcatti, MER, director of the Biomolecular Screening Facility (BSF), two groups at the EPFL. Debio 0826 will benefit from the multiple molecular and genetic tools generated by Dr Radtke's group over the past 10 years, as well as the expertise of Dr Turcatti in the molecular screening field.
'Targeting pathways controlling cell fate specification could generate innovative anti-cancer drugs with anti-tumoural, anti-metastatic and anti-angiogenic properties to treat tumours that are currently resistant to standard therapies,' said Kamel Besseghir, chief executive officer of Debiopharm.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
